Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 1%

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO) were down 1% during trading on Monday . The stock traded as low as GBX 1.58 ($0.02) and last traded at GBX 1.60 ($0.02). Approximately 3,015,726 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 14,640,722 shares. The stock had previously closed at GBX 1.62 ($0.02).

Hemogenyx Pharmaceuticals Trading Down 1.0 %

The company has a market cap of £21.43 million, a price-to-earnings ratio of -159.90 and a beta of 3.06. The company’s 50 day moving average price is GBX 2.26 and its 200 day moving average price is GBX 2.32. The company has a debt-to-equity ratio of 89.95, a quick ratio of 6.72 and a current ratio of 4.07.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.